Lab Tests Show Black-Market Peptides Miss the Labeled Dose

Researchers in Australia commissioned lab testing of black-market peptide vials labeled retatrutide and found that most do not match their stated doses — some contain far more of the experimental drug than the label claims, according to an ABC News investigation published Aug. 28. The findings arrive as Australian doctors treat patients hospitalized with liver failure after injecting counterfeit peptides.

Retatrutide, an Eli Lilly obesity candidate, remains in clinical trials and is not approved for human use. Leeder Analytical, a Melbourne laboratory, tested three vials of the counterfeit product obtained from black-market users at the request of ABC News and University of Queensland (UQ) researchers.

Lab Data: Most Vials Miss the Label

Of the three vials tested, one contained less retatrutide than its label indicated; two contained substantially more. Leeder Analytical’s broader 2026 dataset shows the pattern is not isolated: of 18 counterfeit retatrutide samples tested this year, only one matched its label claim. Roughly 30 percent contained higher concentrations than stated, 30 percent contained less, and one vial contained no retatrutide at all.

Analytical chemist Grace Hamann said the results ran against expectations for unregulated products.

“You would expect if you’re buying an unregulated product that they’d want to cut costs [and include less of the drug] … but the fact that we’ve had almost equal amount to be over 100 per cent than under 100 per cent, surprises me,” Hamann told ABC News.

Hamann said peptide testing now accounts for about half of her lab’s work, with requests arriving almost daily since October 2025.

Why Overdosing Surprised Researchers

The over-concentration finding contradicted patterns seen in other black-market injectables. Tim Piatkowski, a peptide researcher at UQ’s School of Public Health, said steroid testing showed the opposite trend.

“When we tested a number of steroids, we saw underdosing to be hugely prevalent with a very low percentage of overdosed substances,” Piatkowski told ABC News.

Piatkowski and colleagues reported the findings to the journal Drug and Alcohol Review, writing that “although media attention has often focused on counterfeit or adulterated products, these findings suggest that inaccurate dosing alone may represent an important source of risk.”

The dosing findings add a new dimension to Australia’s counterfeit retatrutide crisis, where doctors have hospitalized patients with liver toxicity after black-market injections. Marie Sinclair, a Victoria liver transplant specialist who has treated those patients, said the variability posed a serious danger.

“There is a lot of concern that these unregulated vials of retatrutide may not contain exactly what the manufacturers report that they contain,” Sinclair told ABC News.

Purity Tests Offer Limited Reassurance

The data also complicate the growing “purity testing” practice used by wellness businesses to reassure customers. Hamann said the peptide typically accounts for only about 10 percent of vial contents.

“So, there’s another 90 per cent that’s unaccounted-for, which could contain a different toxin or something else unsafe,” she said.

Sinclair said certificates of analysis can create false confidence because they do not screen for everything. “All that they know from this testing is that there is some retatrutide in their vials. It doesn’t actually tell them if there’s any other contaminants or any other drugs or medications that could be mixed with them,” she said.

That caveat is not an argument against testing — it is an argument for reading results in aggregate rather than vial by vial. Across the gray market as a whole, what 9,997 published lab tests show is the aggregate: dose accuracy, not purity, is the failure that keeps recurring. Where those vials end up is now quantified for one peptide: of 1,039 clinician-documented BPC-157 users — sourcing recorded for 205 of them — 35% came from a gray-market vendor and 36% from a compounding pharmacy (BPC-157 real-world use data, Reuters, September 15, 2026), and the BPC-157 compound guide sets out the compounding route those users are legally limited to. The analysis carries its own disclosure: its authors are employees of nference, a firm that runs research collaborations with biopharmaceutical companies whose products appear in the study, and it states that no external funding was received.

The limitations echo U.S. safety findings: ECRI and the Institute for Safe Medication Practices documented gray-market peptide purity ranging from 5 to 75 percent, with arsenic and lead contamination above limits for sterile injectables, and U.S. regulators have recalled compounded peptide injections over endotoxin contamination.

Regulator: Counterfeit Peptides Are Untested Drugs

Robyn Langham, chief medical advisor at the Therapeutic Goods Administration (TGA), Australia’s medicines regulator, said a product that merely resembles retatrutide cannot be considered equivalent to the clinical-trial drug.

“This is a counterfeit product. Any time you slightly change the molecular structure of a product, especially peptides, you will have a different drug,” Langham told ABC News.

“[Counterfeit peptides] have not been tested in clinical trials, they have not been tested in terms of their manufacturing, and they’ve not been tested for their safety — and people are injecting these into their body.”

Langham said inaccurate concentration is itself a hazard even where contamination is absent. “There can be a risk with the dosage alone,” she said. The TGA has warned against illegal peptides since May as part of a global enforcement wave.

What This Means

The Leeder Analytical data reframes the black-market risk calculus: dose inaccuracy is not a rare failure but the norm, and it cuts both ways. A vial containing far more drug than labeled creates its own toxicity risk; a vial containing none delivers no effect while exposing users to unknown filler material. With retatrutide still in clinical trials — all four core Phase 3 readouts are now positive, but no approval has followed — independent lab data is one of the few reliable windows into what unregulated products actually contain. Because no approved retatrutide exists, any product for sale is counterfeit by definition — see how to spot fake pens and vials. What unverified contents do inside a patient with a chronic condition is documented in the August 2026 case report we cover here. The Drug and Alcohol Review report is expected to provide a peer-reviewed record of the findings.

PeptidesBeat is an independent editorial publication covering peptide policy, research, and industry developments. We do not sell peptides, recommend dosing, or provide medical advice. All content is informational. Peptides referenced may be subject to FDA restrictions; consult a licensed healthcare provider for any therapeutic question.